Skip to main content
TipRanks
Go Ultimate75% OFF

Rodney Markin Insider Profile

4 Followers

Rodney Markin, Director at Cardiff Oncology, holds 31.06K shares in Cardiff Oncology (Ticker: CRDF). Most recently, Rodney Markin Bought 2,900 shares of Cardiff Oncology on Mar 29, 2021 for an estimated value of $29.93K.

Rodney Markin's Trading History

CRDF
Cardiff Oncology
Mar 29, 2021DirectorInformative Buy29.93K$22.55K
CRDF
Insider Shares: 31.06K (0.08%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 29, 2021Informative Buy$29.93K2,900$10.32-73.10%
May 18, 2020Informative Buy$30.00K20,979$1.43+371.00%
Jun 21, 2018Informative Buy$35.02K41,200$0.85-48.10%
Jan 04, 2018Uninformative Buy$5.08K16,667$0.30―
Sep 06, 2017Uninformative Buy$4.21K5,943$0.70―

You May Also Like

Rodney Markin insider profile FAQ

What is the percentage of profitable transactions made by Rodney Markin?
The percentage of profitable transactions made by Rodney Markin is 33%.
What is the average return per transaction made by Rodney Markin?
The average return per transaction made by Rodney Markin is 83.20%.
What stocks does Rodney Markin hold?
Rodney Markin holds: CRDF stocks.
What was Rodney Markin’s latest transaction?
Rodney Markin’s latest transaction was an Informative Buy of $29.93K.
What was Rodney Markin's most profitable transaction?
Rodney Markin’s most profitable transaction was an Informative Buy of CRDF stock on May 18, 2020. The return on the trade was 371.00%.
What is Rodney Markin's role in Cardiff Oncology?
Rodney Markin's role in Cardiff Oncology is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.